Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) is a Healthcare company (Biotechnology) with a market capitalization of $146M. The Maz Rating grades it against the other companies in its sector.
Zentalis Pharmaceuticals, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $1.49, Zentalis Pharmaceuticals, Inc. trades at 0.6x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -75.8%, return on invested capital of -62.3% and a free cash flow yield of -114.0%. On the balance sheet: a debt-to-equity ratio of 0.18 and a current ratio of 7.33. Over the past 52 weeks the share price ranged from $1.28 to $6.95, with a beta of 1.93.
Zentalis Pharmaceuticals, Inc. does not currently pay a dividend.
12 Wall Street analyst ratings cover the stock: 9 Buy and 3 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Zentalis Pharmaceuticals, Inc. (ZNTL) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 115.4% / 30% · Interest income / Revenue 0.00% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 115.4% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 0.00% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 115.4% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 4.54% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 83.8% / 33.33% · Receivables / Avg Assets (4Q) 0.36% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 84.7% / 33.33% · (Cash+Recv) / Total Assets 84.7% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
No. As of September 2026, Zentalis Pharmaceuticals, Inc. (ZNTL) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Zentalis Pharmaceuticals, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m).
Zentalis Pharmaceuticals, Inc. reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.